Savara (SVRA)
NASDAQ:SVRA
Top Page
Savara
(NASDAQ:SVRA)
Select Model
Select Model
Rating:46Neutral
Price Target:
$5.00
▼(-2.72% Downside)
Action:ReiteratedDate:03/14/26
The score is primarily held down by the financial profile—no revenue, accelerating losses, and high, worsening cash burn—alongside weak technical momentum. A comparatively solid equity base with manageable debt and mildly positive corporate updates provide limited offset, while valuation signals are constrained by negative earnings.
Positive Factors
Balance Sheet Strength
A meaningful increase in stockholders’ equity to ~$203M, combined with modest debt (~$29.9M; debt/equity ~0.32), provides Savara with durable financial flexibility typical for a development-stage biotech. This backing helps absorb R&D and pre-commercial costs, supports borrowing capacity, and reduces immediate liquidity strain during regulatory execution.
Negative Factors
Pre-Revenue Status
Savara remains a pre-revenue company with no product sales through 2024 and TTM, meaning it must rely on external financing or milestone receipts to fund operations. This structural lack of recurring revenue elevates long-term financing and execution risk, making sustainable profitability contingent on successful regulatory approval and commercial launch.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A meaningful increase in stockholders’ equity to ~$203M, combined with modest debt (~$29.9M; debt/equity ~0.32), provides Savara with durable financial flexibility typical for a development-stage biotech. This backing helps absorb R&D and pre-commercial costs, supports borrowing capacity, and reduces immediate liquidity strain during regulatory execution.
Read all positive factors
Savara (SVRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.05B
Dividend YieldN/A
Average Volume (3M)1.79M
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue GrowthN/A
EPS Growth-22.39%
CountryUS
Employees59
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.13
Shares Outstanding204,657,500
10 Day Avg. Volume2,642,326
30 Day Avg. Volume1,792,158
Financial Highlights & Ratios
PEG Ratio-1.08
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-774.62
Enterprise Value/Ebitda-8.45
Forecast
1Y Price Target
$10.25Price Target Upside99.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$16.54M
Savara Business Overview & Revenue Model
Company Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the...
How the Company Makes Money
null...
Savara Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -245.00K | -78.03M | -44.26M | -27.88M | -28.99M |
| EBITDA | -123.46M | -102.27M | -59.13M | -38.01M | -40.50M |
| Net Income | -118.84M | -95.88M | -54.70M | -38.15M | -43.01M |
Balance Sheet | |||||
| Total Assets | 253.44M | 212.88M | 177.56M | 139.78M | 176.60M |
| Cash, Cash Equivalents and Short-Term Investments | 235.70M | 196.33M | 162.32M | 125.88M | 161.17M |
| Total Debt | 29.91M | 26.73M | 26.49M | 26.14M | 25.79M |
| Total Liabilities | 50.30M | 41.43M | 37.19M | 32.00M | 32.10M |
| Stockholders Equity | 203.13M | 171.45M | 140.37M | 107.78M | 144.50M |
Cash Flow | |||||
| Free Cash Flow | -101.06M | -89.11M | -51.36M | -34.56M | -40.14M |
| Operating Cash Flow | -101.04M | -89.09M | -51.06M | -34.55M | -40.08M |
| Investing Cash Flow | -18.44M | -39.94M | -57.12M | 52.65M | -69.46M |
| Financing Cash Flow | 137.81M | 117.58M | 82.78M | 87.00K | 120.81M |
Savara Technical Analysis
Negative
5.14
Price Trends
5.54
Negative
5.55
Negative
4.30
Positive
Market Momentum
-0.13
Positive
43.74
Neutral
67.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SVRA, the sentiment is Negative. The current price of 5.14 is below the 20-day moving average (MA) of 5.32, below the 50-day MA of 5.54, and above the 200-day MA of 4.30, indicating a neutral trend. The MACD of -0.13 indicates Positive momentum. The RSI at 43.74 is Neutral, neither overbought nor oversold. The STOCH value of 67.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SVRA.
Savara Risk Analysis
Savara disclosed 36 risk factors in its most recent earnings report. Savara reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Savara Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $476.79M | 2.10 | 240.83% | ― | 79.13% | 2798.12% | |
56 Neutral | $1.16B | -5.93 | -27.17% | ― | ― | -103.95% | |
54 Neutral | $1.47B | -8.84 | 76.70% | ― | ― | ― | |
53 Neutral | $1.65B | -101.81 | 1813.84% | ― | 196.42% | 53.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.19B | -13.39 | -42.90% | ― | ― | 17.23% | |
46 Neutral | $1.05B | -11.28 | -84.01% | ― | ― | -22.39% |
* Healthcare Sector Average
SVRA
Savara
5.14
2.37
85.56%
RIGL
Rigel
25.81
7.82
43.47%
ANAB
AnaptysBio
57.40
38.81
208.77%
OLMA
Olema Pharmaceuticals
13.67
9.91
263.56%
NBTX
Nanobiotix
29.95
26.37
736.59%
BCAX
Bicara Therapeutics Inc.
18.37
5.34
40.98%
Savara Corporate Events
Business Operations and Strategy
Savara Signs Long-Term Lease for New Headquarters
Positive
Mar 13, 2026
On March 10, 2026, Savara Inc. signed a lease with ML7 Yardley Partners, LP for about 10,795 square feet of office space at 19 W. College Avenue, Suite 200, in Yardley, Pennsylvania, with plans to relocate its headquarters there. The lease term be...
Business Operations and StrategyRegulatory Filings and Compliance
Savara Enters New Material Definitive Agreement and Obligation
Neutral
Jan 27, 2026
Savara Inc., a Delaware corporation, reported on January 27, 2026, that it had executed a material definitive agreement, as disclosed under Item 1.01 of its filing, and confirmed that the report was duly authorized and signed by Chief Financial an...
Business Operations and StrategyProduct-Related Announcements
Savara Highlights Autoimmune PAP Burden in Updated Presentation
Positive
Jan 9, 2026
In January 2026, Savara updated its corporate presentation to provide an expanded overview of autoimmune pulmonary alveolar proteinosis (autoimmune PAP), the burden of disease, and the limitations of existing care such as whole lung lavage, an inv...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.